Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) and has been shown to provide clinical benefits in combination with platinum-based chemotherapy in nonsquamous NSCLC [9]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.